UBS Group
AGN.PRA

UBS Group’s Allergan plc AGN.PRA Stock Holding History

UBS Group’s Portfolio AGN.PRA Stock Details AGN.PRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,508
Closed -$884K – 8503
2017
Q4 		$884K Buy
1,508
+652
+76% +$421K ﹤0.01% 3883
2017
Q3 		$632K Sell
856
-960
-53% -$797K ﹤0.01% 4043
2017
Q2 		$1.57M Buy
1,816
+849
+88% +$711K ﹤0.01% 3217
2017
Q1 		$820K Buy
967
+212
+28% +$176K ﹤0.01% 3693
2016
Q4 		$576K Buy
755
+60
+9% +$45.3K ﹤0.01% 4008
2016
Q3 		$571K Buy
695
+56
+9% +$48.4K ﹤0.01% 3836
2016
Q2 		$533K Buy
639
+597
+1,421% +$499K ﹤0.01% 3838
2016
Q1 		$39K Sell
42
-422
-91% -$403K ﹤0.01% 5695
2015
Q4 		$477K Buy
464
+422
+1,005% +$424K ﹤0.01% 3987
2015
Q3 		$40K Buy
+42
New +$43.8K ﹤0.01% 6030

Other funds holding AGN.PRA

PWS
Peloton Wealth Strategists Indianapolis, Indiana $271M AUM 19.14% 1-Year Est. Return

UBS Group's AGN.PRA Position: Q1 2018 in Review

UBS Group sold out of Allergan plc (AGN.PRA) in Q1 2018, closing a stake of 1,508 shares — an estimated $884K sold.

UBS Group first reported a position in AGN.PRA in Q3 2015 and held it in 10 quarters. The position peaked at $1.57M in Q2 2017. 1 fund tracked by Wall St. Rank holds AGN.PRA as of Q1 2018.

  • UBS Group reported no remaining Allergan plc position as of Q1 2018 after selling out during the quarter.
  • UBS Group sold 1,508 Allergan plc shares in Q1 2018, an estimated $884K.
  • UBS Group first reported a position in Allergan plc in Q3 2015 and held it in 10 quarters.
  • UBS Group's Allergan plc position peaked at $1.57M in Q2 2017.
  • 1 fund tracked by Wall St. Rank held Allergan plc as of Q1 2018.

Based on UBS Group's 13F filing for Q1 2018, filed 15 May 2018.